Cancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition
Published on: Wednesday, August 16th, 2017 View all Media
Conference call scheduled for Tuesday, August 22, 2017- 8:30 AM Eastern
RUTHERFORD, N.J. and LOS ANGELES, August 16, 2017 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX, The Company and CGI), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will host an investor and analyst call and webcast on Tuesday, August 22, 2017 at 8:30 am Eastern. CGI will discuss the strategy and business rationale of the recent transformative and accretive acquisition of vivoPharm.
CGI’s acquisition of vivoPharm, announced on August 14, 2017, will significantly strengthen the Company’s position as a leader for oncology discovery and early phase clinical development and testing for biotechnology and pharmaceutical companies. With over a decade of experience in delivering a wide range of discovery and preclinical services to support drug development, target validation and biomarker analysis, vivoPharm has supported over 200 IND submissions for innovative therapies, with a significant focus on immuno-oncology.
Hosted by CGI’s CEO and President, Mr. Panna Sharma, the call will introduce investors and analysts to new members of the CGI team, including Dr. Ralf Brandt, former CEO and Managing Director of vivoPharm, who now serves as the President of Discovery & Early Development Services at CGI.
Mr. Sharma will also provide insight into both operational and customer synergies that will result from the integration of vivoPharm, as well as the long-term strategy for growth. Additional details will also be provided on vivoPharm’s specialized tumor and disease models, toxicology and pharmacology services, biomarker analysis and animal imaging capabilities that are expected to provide CGI new opportunities to deepen its relationships with existing biopharma customers through additional discovery and downstream molecular work, while bolstering the Company’s previously announced initiative aimed at early-phase drug repurposing and drug rescue programs.
The call details are noted in the table below.
|CONFERENCE CALL & WEBCAST|
|Tuesday, August 22, 2017, 8:30 am Eastern Time|
|Replays – Available through September 5, 2017|
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, Australia and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.